TailorDose®-II: Therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer
This study, called TailorDose®-II, is exploring how different levels of common breast cancer medications affect patients. Researchers want to understand if getting too much or too little of a drug affects side effects, especially things like anaemia (when your blood doesn’t have enough red cells, making you feel very tired). They are also looking into whether different drug levels impact a person's overall quality of life, their physical health, and how well the treatment works against the cancer. The study is also checking if genetics play a role in how a person processes these medicines and how factors like age or smoking habits might influence drug levels. The ultimate goal is to find the perfect dose for each individual patient to get the best treatment with the fewest unwanted side effects.
At a glance
What is this study about?
Imagine you're taking medicine for breast cancer. This study, called TailorDose®-II, is like a careful detective looking closely at how much medicine gets into your body and what effects that amount has. The main idea is that everyone is different, and the 'right' dose of a medicine might not be the same for everyone. Sometimes, a standard dose might be too much for one person, leading to more side effects, while for another, it might not be quite enough to work as well as it could.
Researchers are particularly interested in a side effect called anaemia, which can make you feel very tired. They want to see if people who have higher levels of the cancer medicine in their body have more problems with anaemia compared to those with lower levels. But it’s not just about side effects; the study also wants to see if certain medicine levels are linked to how well the treatment fights the cancer, and importantly, how these levels affect your overall quality of life – how you feel day-to-day. They're also checking if things like your age, body size, or even your genes can influence how your body handles these medicines.
The information gathered from this study is really important because it could help doctors in the future give each patient a dose that's just right for them. This personalised approach aims to make treatment more effective and reduce unpleasant side effects, helping people with breast cancer feel better and have a better quality of life during and after their treatment. It's about finding that sweet spot for each individual patient.
Key takeaways
- The study aims to personalise breast cancer treatment.
- It checks how current chemotherapy drugs affect patients.
- Researchers are looking for links between drug levels and side effects like anaemia.
- The study explores how drug levels relate to a patient's quality of life.
- It could help doctors find the ideal drug dose for each person in the future.
Who may be eligible?
This study is only for women who have breast cancer. To join, you must be at least 18 years old, but there's no upper age limit, meaning older women can also take part.
The study is open to female patients who are receiving specific types of chemotherapy treatments for their breast cancer. These treatments include medicines like Doxorubicin, Paclitaxel, Docetaxel, Epirubicin, and Cyclophosphamide. Your doctor will be able to confirm if your current treatment plan matches the study's requirements.
It's important to talk to your healthcare team if you're interested in joining, as they will check all the detailed requirements to make sure it's suitable and safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you a woman diagnosed with breast cancer?
- Are you 18 years old or older?
- Are you currently receiving chemotherapy which includes drugs like Doxorubicin, Paclitaxel, Docetaxel, Epirubicin, or Cyclophosphamide?
- Are you able to provide blood samples for monitoring?
What does participation involve?
If you decide to take part in this study, you won't be given new or experimental drugs. Instead, the study will involve measuring the levels of the standard breast cancer medicines you're already receiving. This may involve providing blood samples, which might sometimes be taken from your fingertip (like a diabetes test) instead of from a vein, to measure how much of the medicine is in your body. You might also be asked to answer questions about your quality of life and how you're feeling as part of regular check-ups.
Researchers will carefully compare your drug levels with any side effects you experience, how well your treatment is working, and generally how you're doing. There won't be any extra hospital visits just for the study; these measurements and questions will likely coincide with your planned treatment appointments. The total duration of your involvement would depend on your individual treatment plan.
Potential risks and benefits
Locations (1)
- —UnverifiedSweden
Common questions
What kind of cancer is this study for?
This study is for women with a type of breast cancer called 'breast cancer female NOS' (Not Otherwise Specified).
What medicines are being looked at?
The study focuses on common chemotherapy drugs for breast cancer, including Doxorubicin, Paclitaxel, Docetaxel, Epirubicin, and Cyclophosphamide.
Why is the study measuring drug levels?
The study wants to see how the amount of medicine in your body affects side effects, like feeling tired (anaemia), and how well the treatment works.
Will I get a new treatment in this study?
No, you will receive your usual, standard breast cancer treatment. The study is about monitoring and learning from these existing treatments.
Can men join this study?
No, this specific study is only open to women with breast cancer.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.